Intuitive Surgical, Inc. stock (US46120E6023): Robotic surgery leader posts solid Q1 results and raises guidance

Intuitive Surgical, Inc. stock reacts to stronger-than-expected first-quarter 2026 revenue and an upward revision to its full-year guidance, underscoring demand for da Vinci robotic systems and procedures.

Intuitive Surgical, Inc. stock has moved higher after the robotic surgery leader reported stronger-than-expected first-quarter 2026 revenue and raised its full-year guidance, highlighting continued demand for its da Vinci systems and procedures. Revenue for the quarter ended March 31, 2026, reached 1.89 billion USD, up about 15% year-over-year, driven by growth in both system placements and procedure volumes, according to the company’s earnings release and accompanying investor presentation.

The stock traded at 1,045.20 USD on May 7, 2026, on Nasdaq, according to Nasdaq as of 05/07/2026. Intuitive Surgical also raised its 2026 revenue outlook to a range of 7.75–7.95 billion USD, up from the prior 7.5–7.7 billion USD band, reflecting confidence in continued procedure growth and system utilization across its installed base.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Intuitive Surgical, Inc.
• Sector/industry: Medical technology / robotic surgery
• Headquarters/country: United States
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: da Vinci surgical systems, instruments and accessories, service contracts
• Home exchange/listing venue: Nasdaq (ticker: ISRG)
• Trading currency: USD

Intuitive Surgical, Inc.: core business model

Intuitive Surgical, Inc. designs, manufactures, and sells robotic-assisted surgical systems, primarily the da Vinci platform, which enables minimally invasive procedures across urology, gynecology, general surgery, cardiothoracic, and other specialties. The company’s business model combines high-margin capital equipment sales with recurring revenue from instruments, accessories, and service contracts tied to its installed base of systems.

The da Vinci systems are typically sold to hospitals and surgical centers, which then perform procedures using proprietary instruments and accessories that Intuitive supplies. This recurring revenue stream, often referred to as “consumables,” tends to be more predictable and less cyclical than system sales, supporting stable margins and cash flow generation over time.

Main revenue and product drivers for Intuitive Surgical, Inc.

Intuitive Surgical’s main revenue drivers are system placements, procedure volumes, and utilization of its installed base. Growth in system placements expands the installed base, while higher procedure volumes and utilization rates drive demand for instruments, accessories, and service contracts. In the first quarter of 2026, both system placements and procedure volumes contributed to the 15% year-over-year revenue increase, according to the company’s earnings release.

The company’s focus on expanding into new surgical specialties and geographies, as well as on improving system efficiency and workflow integration, supports long-term growth. Intuitive also invests in research and development to enhance its robotic platforms and expand the range of procedures that can be performed with its systems, which in turn can increase adoption and utilization rates.

Conclusion

Intuitive Surgical, Inc. stock has reacted positively to the company’s first-quarter 2026 results and raised full-year guidance, which highlight continued demand for robotic-assisted surgery and strong execution across its core markets. The combination of growing procedure volumes, an expanding installed base, and recurring revenue from instruments, accessories, and service underpins the firm’s long-term growth profile.

For US investors, Intuitive Surgical represents a leading exposure to the global shift toward minimally invasive, robotic-assisted surgery, with a dominant position in the da Vinci ecosystem. However, the stock trades at a premium valuation, and investors should weigh the company’s growth prospects against risks such as competitive pressures, regulatory developments, and potential slowdowns in procedure growth.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.